External evaluation of LIAISON® tumour marker assays on the fully automated chemiluminescent LIAISON® immunoassay analyser

Clinical Laboratory

Volumn 46, Issue 3-4, 2000, Pages 169-179

  Molina, Rafael ^a   Bonfrer, Johannes ^b   Banfi, Guiseppe ^c   Bugugnani, Marie José ^d   Cornu, Francois ^e   Hannemann Pohl, Kurt ^f   Hubl, Walter ^g   Merz, Ottorino ^h   Bach, Marion ⁱ   Mack, Michael ⁱ  

^a HOSPITAL CLÍNIC   (Spain)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d CENTRE HOSPITALIER   (France)

^e Laboratoire Biolor   (France)

^f Marienkrankenhaus   (Germany)

^g Krankenhaus Friedrichstadt   (Germany)

^h SANTA CHIARA HOSPITAL   (Italy)

ⁱ Byk Sangtec Diagnostica ^*  (Germany)

Author keywords

Chemiluminescence; LIAISON ; Multicentre evaluation; Random access analyser; Reference ranges; Tumour markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EDETIC ACID; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ARTICLE; CHEMOLUMINESCENCE; IMMUNOASSAY; INTERMETHOD COMPARISON; PLASMA; SERUM;

HUMANS; IMMUNOASSAY; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 6744243266     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gold P, Freedman, SO. Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques. J Exp Med 1965; 121: 439-462.
2. Stamey TA, Yang N, Hay AR, et al. Prostate specific antigen as a serum marker for adenoma of the prostate. N Engl J Med 1987; 317:909-916.
3. Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund C, Mäkela O. Comparison of a new tumour marker, CA 19-9. with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984; 37:218
4. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883.
5. Tomlinson IPM, Whyman JA, Barrett JA, Kremer JK. Tumor marker CA 15-3. Possible uses in the routine management of breast cancer. Eur J Cancer 1995; 31A:899-902.
6. Koprowsky H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genetics 1979; 5(6):957-72.
7. Wielders JPM, Bartels CT, Bank CMC, Meek JC, van DieijenVisser MP, Brombacher PJ. The diagnostic value of NSE and CEA analyses in patients with carcinoma of the lung. J lung Chem Clin Biochem 1990; 28:225-31.
8. NCCLS proposed guideline EP6-P. Evaluation of the linearity of quantitative analytical methods. Villanova, PA National Committee for Clinical Laboratory Standards, 1992
9. ECCLS guidelines for the evaluation of analysers in clinical chemistry. ECCLS Document Vol. 3, No. 2, June 1986
10. Feldmann U, Schneider B, Klinkers H, Haeckel R. A multivariate approach for the biometric comparison of analytical methods in clinical chemistry. J Clin Chem Clin Biochem 1981; 19:121-37.
11. Spencer CA, LoPrestl JS, Patel A, Guttler RB, Eigen A, Shen D, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrin Metab 1990; 70(2):453-60.
12. Klapdor R. Arbeitsgruppe Qualitätskontrolle und Standardisierung von Tumormarkertests im Rahmen der Hamburger Symposien über Tumormarker. Tumordiagn. u. Ther. 13 (1992): XIX-XII
13. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154 1090-5
14. Pittaway DE Assay characteristics of the immunoradiometric method for CA-125. Fertil Steril 1989; 51:348-50.
15. Wener MH, Daum PR, Brawer MK. Variation in measurement of prostate-specific antigen: importance of method and lot variability. Clin Chem 1995; 41:1730-7.
16. Cole TG, Johnson D, Eveland BJ, Nahm MH. Cost-effective method for detection of 'hook effect' in tumor marker immunometric assays. Clin Chem 1993; 39:695-6
17. Beinlich CJ, Carpenter RH. Automated and manual quantitative assays of choriogonadotropin in serum compared. Clin Chem 1987; 33:167-9.